A Phase 1 interventional study of XB010 and Pembrolizumab in Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer and Head and Neck Squamous Cell Cancer, sponsored by Exelixis. Recruiting at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Exelixis · Phase 1, Interventional, and Treatment
How we know · 7 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
This study consists of Dose-Escalation and Cohort-Expansion Stages. The Dose-Escalation Stage is designed to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]) of XB010 as a single agent, and to evaluate XB010 monotherapy RDE(s) in combination with pembrolizumab. The Cohort-Expansion Stage is designed to explore the clinical activity and further characterize the safety and tolerability of XB010 as monotherapy in multiple tumor-specific cohorts.
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, , or recurrent.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
XB010 will be administered at escalating dose levels every 3 weeks in cohorts of 3-12 subjects
Drug: XB010
XB010+Pembrolizumab will be administered at escalating dose levels every 3 weeks in cohorts of 3-12 subjects
Drug: XB010 · Drug: Pembrolizumab
XB010 will be administered at the recommended dose for expansion (RDE) every 3 weeks in the following tumor-specific cohorts: non-small cell lung cancer (NSCLC), hormone-receptor-positive breast cancer (HR+BC), head and neck squamous cell cancer (HNSCC), esophageal squamous cell cancer (ESCC), endometrial cancer (EC) and triple-negative breast cancer (TNBC)
Drug: XB010
IV administration of XB010
IV administration of Pembrolizumab
Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010
To determine the MTD and/or RDE(s) for further evaluation of IV administration of XB010 alone and in combination therapy.
Time frame: 18 months
Dose-Escalation Stage: Safety of XB010
To evaluate the safety of XB010 alone and in combination therapy through the evaluation of incidence and severity of nonserious adverse events (AEs) and serious adverse events (SAEs)
Time frame: 18 months
Dose-Escalation Stage: Duration of exposure of XB010 [Tolerability]
To evaluate the tolerability of XB010 alone and in combination therapy through the evaluation of the duration of exposure of each component
Time frame: 18 months
Dose-Escalation Stage: Dose intensity of XB010 [Tolerability]
To evaluate the tolerability of XB010 alone and in combination therapy through the evaluation of the dose intensity of each component
Time frame: 18 months
Cohort-Expansion Stage: Preliminary antitumor activity of XB010
Objective Response Rate (ORR) as assessed by the Investigator per RECIST 1.1
Time frame: 24 months
Dose-Escalation Stage: Maximum Plasma Concentration (Cmax) of XB010
To evaluate the maximum plasma concentration of XB010 alone and in combination.
Time frame: 18 Months
Dose-Escalation Stage: Time to Maximum Plasma Concentration (Tmax) of XB010
To evaluate the time to maximum plasma concentration of XB010 alone and in combination.
Time frame: 18 Months
Dose-Escalation Stage: Clearance of XB010
To evaluate the volume of plasma cleared of XB010 alone and in combination for a specified time period
Time frame: 18 Months
Dose-Escalation Stage: Area Under the Plasma Concentration Curve (AUC) of XB010
To measure the Area Under the Plasma Concentration Curve of XB010 alone and in combination
Time frame: 18 Months
Dose-Escalation Stage: Minimum Plasma Concentration (Cmin) of XB010
To evaluate the minimum plasma concentration of XB010 alone and in combination
Time frame: 18 Months
Dose-Escalation Stage: Immunogenicity of XB010
To assess the immunogenicity of XB010 alone and in combination as measured by anti-drug antibody (ADA) analysis
Time frame: 18 Months
Cohort-Expansion Stage: Duration of exposure of XB010 [Tolerability]
To evaluate the tolerability of XB010 through the evaluation of the duration of exposure
Time frame: 24 Months
Cohort-Expansion Stage: Dose intensity of XB010 [Tolerability]
To evaluate the tolerability of XB010 through the evaluation of the dose intensity
Time frame: 24 Months
Cohort-Expansion Stage: Maximum Plasma Concentration (Cmax) of XB010
To evaluate the maximum plasma concentration of XB010
Time frame: 24 Months
Cohort-Expansion Stage: Time to Maximum Plasma Concentration (Tmax) of XB010
To evaluate the time to maximum plasma concentration of XB010
Time frame: 24 Months
Cohort-Expansion Stage: Clearance of XB010
To evaluate the volume of plasma cleared of XB010 for a specified time period
Time frame: 24 Months
Cohort-Expansion Stage: Area Under the Plasma Concentration Curve (AUC) of XB010
To measure the Area Under the Plasma Concentration Curve of XB010
Time frame: 24 Months
Cohort-Expansion Stage: Minimum Plasma Concentration (Cmin) of XB010
To evaluate the minimum plasma concentration of XB010
Time frame: 24 Months
Cohort-Expansion Stage: Immunogenicity of XB010
To assess the immunogenicity of XB010 as measured by anti-drug antibody (ADA) analysis
Time frame: 24 Months
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Nov 2026, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esophageal Squamous Cell Carcinoma →